In the conventional systems of the currently valid guidelines, risk stratification is based on serology (PSA < 10, 10–20 oder > 20) and the tumor size estimated on the basis of the biopsy result (GS, numbers of positive cores and percentage of the cores involved). This evidence concerns the gene KLK3 and neoplasm.